COVID-19 Drug Discovery Using Intensive Approaches.
COVID-19
coronavirus
drug discovery
drug repositioning
infection
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
18 Apr 2020
18 Apr 2020
Historique:
received:
27
03
2020
revised:
09
04
2020
accepted:
14
04
2020
entrez:
25
4
2020
pubmed:
25
4
2020
medline:
28
4
2020
Statut:
epublish
Résumé
Since the infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in China during December 2019, the coronavirus disease 2019 (COVID-19) has spread on a global scale, causing the World Health Organization (WHO) to issue a warning. While novel vaccines and drugs that target SARS-CoV-2 are under development, this review provides information on therapeutics which are under clinical trials or are proposed to antagonize SARS-CoV-2. Based on the information gained from the responses to other RNA coronaviruses, including the strains that cause severe acute respiratory syndrome (SARS)-coronaviruses and Middle East respiratory syndrome (MERS), drug repurposing might be a viable strategy. Since several antiviral therapies can inhibit viral replication cycles or relieve symptoms, mechanisms unique to RNA viruses will be important for the clinical development of antivirals against SARS-CoV-2. Given that several currently marketed drugs may be efficient therapeutic agents for severe COVID-19 cases, they may be beneficial for future viral pandemics and other infections caused by RNA viruses when standard treatments are unavailable.
Identifiants
pubmed: 32325767
pii: ijms21082839
doi: 10.3390/ijms21082839
pmc: PMC7215413
pii:
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Society for the Promotion of Science
ID : 15H05791; 17H04282; 17K19698; 18K16356; 18K16355
Organisme : Japan Agency for Medical Research and Development
ID : 16cm0106414h0001; 17cm0106414h0002
Organisme : Princess Takamatsu Cancer Research Fund
ID : H30
Références
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Drug Discov Ther. 2020;14(1):58-60
pubmed: 32147628
JAMA. 2020 Mar 4;:
pubmed: 32129805
Pharmacol Ther. 2020 May;209:107512
pubmed: 32097670
Sci Transl Med. 2017 Jun 28;9(396):
pubmed: 28659436
J Virol. 2006 Sep;80(17):8362-70
pubmed: 16912287
Sci Rep. 2017 Mar 06;7:43395
pubmed: 28262699
Nature. 2013 Mar 14;495(7440):251-4
pubmed: 23486063
mBio. 2018 Mar 6;9(2):
pubmed: 29511076
Adv Virus Res. 2000;55:135-84
pubmed: 11050942
Amino Acids. 2015 Apr;47(4):693-705
pubmed: 25534429
Curr Med Chem. 2008;15(10):997-1005
pubmed: 18393857
Antimicrob Agents Chemother. 2020 Apr 21;64(5):
pubmed: 32152082
Cancer Res. 2019 Apr 1;79(7):1426-1437
pubmed: 30765602
Nucleic Acids Res. 1998 May 1;26(9):2050-7
pubmed: 9547258
Biosci Trends. 2020 Mar 16;14(1):72-73
pubmed: 32074550
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Nature. 2003 Nov 27;426(6965):450-4
pubmed: 14647384
Nat Immunol. 2011 Feb;12(2):137-43
pubmed: 21217758
J Med Virol. 2020 Feb 25;:
pubmed: 32096567
Cell Res. 2013 Feb;23(2):300-2
pubmed: 23208422
Nature. 2010 Nov 18;468(7322):452-6
pubmed: 21085181
Nat Rev Drug Discov. 2019 Jan;18(1):41-58
pubmed: 30310233
Oncogene. 2019 Jan;38(2):244-260
pubmed: 30089817
Cell. 2010 Feb 5;140(3):397-408
pubmed: 20144762
RNA Biol. 2008 Jul-Sep;5(3):140-4
pubmed: 18769134
J Clin Invest. 2010 Sep;120(9):3326-39
pubmed: 20697159
Proc Natl Acad Sci U S A. 2018 May 29;115(22):E5135-E5143
pubmed: 29760102
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Mar 02;48(0):E004
pubmed: 32120458
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
Cell Mol Life Sci. 2016 Mar;73(5):985-1001
pubmed: 26658914
J Biol Chem. 2020 Apr 10;295(15):4773-4779
pubmed: 32094225
J Infect. 2020 Mar 11;:
pubmed: 32171872
Nature. 2016 Mar 17;531(7594):381-5
pubmed: 26934220
Science. 2006 Nov 10;314(5801):997-1001
pubmed: 17038589
Virol Sin. 2016 Feb;31(1):3-11
pubmed: 26847650
J Biol Chem. 2011 Feb 25;286(8):6602-13
pubmed: 21148553
Science. 2020 Mar 27;367(6485):1444-1448
pubmed: 32132184
Prog Nucleic Acid Res Mol Biol. 1979;22:327-53
pubmed: 523634
mBio. 2020 Feb 11;11(1):
pubmed: 32047128
Sci China Life Sci. 2020 Mar;63(3):457-460
pubmed: 32009228
Nat Commun. 2020 Mar 27;11(1):1620
pubmed: 32221306
Biochem J. 2009 Dec 23;425(2):295-302
pubmed: 20025612
Nature. 2013 Feb 7;494(7435):60-4
pubmed: 23334420
Science. 2006 Nov 10;314(5801):994-7
pubmed: 17038590
JAMA. 2020 Mar 11;:
pubmed: 32159775
Lancet Infect Dis. 2003 Nov;3(11):722-7
pubmed: 14592603